ARID1A and cancer: Based on these findings, we hypothesized that cancer-promoting mutations (i.e., ARID1A) increase PRC2 complex activity (including expression of the EZH2 component) and induce an HCV/alcohol-mediated stem cell program (slow growing cells), leading to TIC-initiated HCC development (Figure 2C).